Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy.
Fifty-five patients undergoing chemotherapy for various neoplastic processes were treated with trimethobenzamide or placebo to control nausea and vomiting. Trimethobenzamide was shown to be significantly better than placebo in relieving periodic and total nausea over the 48-hour study. Vomiting incidence was also reduced in the group receiving trimethobenzamide. Differences were noted in the degree of emetic stimulus associated with different chemotherapeutic regimens. No side effects attributable to trimethobenzamide were recorded.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010919:Placebos; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001549:Benzamides; D010919:Placebos; C100146:trimethobenzamide